Our mission

To enable current and next-generation therapeutics to improve and save the lives of patients.

Our values


Our people are our most important asset, and we are dedicated to building the most talented and diverse workforce in our industry. We are committed to the growth and well-being of our team, and expect them to work collaboratively and act with the highest level of integrity.


Recognizing that each product we touch directly impacts a patient’s life, we maintain an uncompromising focus on quality, compliance, and excellence in delivery.


We strive to be better every 30 days. We challenge our people to continually find ways to improve how we deliver the best service to our customers, and to leverage our scientific and technical expertise to advance industry-leading technology.

Our vision

To be the leading development and manufacturing partner for advanced pharmaceuticals requiring complex chemical synthesis.



Our locations

Click on a location to learn about our capabilities.

  • Devens, MA, USA
  • North Andover, MA, USA
  • Wayne, PA, USA
  • West Deptford, NJ, USA
  • Edinburgh, UK
  • Cambridge, UK

Our certifications


FDA Inspected

MHRA Inspected


Leadership team

Mike Riley, CEO

Mike Riley joined Veranova as Chief Executive Officer in May 2023. Mike has over 25 years of professional experience, the majority of which has been spent in the pharmaceutical contract development and manufacturing (CDMO) industry. Prior to joining Veranova, he spent 19 years at Catalent, Inc., most recently serving as President of Biotherapeutics. During his tenure at Catalent, Mike led and built Catalent’s biologics business into a leading service provider for advanced biologics modalities, including proteins, monoclonal antibodies and Antibody Drug Conjugates. Mike served in multiple executive positions at Catalent and was part of the core leadership team that transformed Catalent from its inception into an S&P 500 company. He began his career as a management consultant for Marakon Associates, providing strategic advisory to companies across multiple industries. Mike holds a B.A. degree from Duke University, and an MBA from The Wharton School, University of Pennsylvania.

Scott Lassonde, SVP, CFO

Scott Lassonde

Scott Lassonde joined Veranova as Senior Vice President and Chief Financial Officer in March 2024. Scott has over 14 years of experience as a Chief Financial Officer in private equity-backed manufacturing-based businesses. Prior to joining Veranova, he served as CFO at Lacerta Group, where he contributed to the company’s focus on sustainability in the packaging manufacturing industry. Scott began his career at General Electric in the Financial Management Program, followed by roles of increasing responsibility over twelve years. Scott holds a Bachelor’s Degree from Dartmouth College, and an MBA from The University of Chicago Booth School of Business.

Rohtash Kumar, SVP, CTO

Rohtash Kumar joined Veranova as SVP, Development Operations and Chief Technical Officer in May 2023. Rohtash brings deep experience in the CDMO industry, leading technical teams engaged in the discovery and development of new products for use in clinical trials, as well as successfully running programs for commercial supply of APIs in the branded market. Prior to joining Veranova, Rohtash served as Site Head at Bachem Americas Inc. where he worked for 8 years holding different positions including VP of API Manufacturing. Prior to Bachem, Rohtash worked with Sigma-Aldrich as Manager of R&D and Manufacturing. In the early part of his career, Rohtash worked at Toronto Research Chemicals as a Group Leader, and at Apotex as Senior Research Scientist. Rohtash holds a Ph.D. in Organic Chemistry from Delhi University, and an MBA – Production Management from Chaudhary Charan Singh University. Rohtash completed postdoctoral work at the University of Alberta, and at the National Research Council of Canada.

Ken Zrebiec, SVP, Manufacturing Operations

Ken Zrebiec has served as SVP, Manufacturing Operations since December 2020. With over 20 years of experience in the production of active pharmaceutical ingredients, Ken has proven leadership in site management, supply chain, project management, and environmental, health, and safety. Prior to Veranova, Ken held senior operational roles with Siegfried in the US and Switzerland and was the Director of Supply Chain at Endo Pharmaceuticals.

Ken has been on the SOCMA Board of Governors since 2018 and has been a member of the SOCMA Executive Board since 2020. Ken holds a B.S. degree in Chemical Engineering and an MBA in Operations Management from the University of Delaware.

Victoria Brown, SVP, CHRO

Victoria Brown joined Veranova as Senior Vice President and Chief Human Resources Officer in August 2023. Victoria joins Veranova with over 25 years of professional experience, including nearly 12 years in leadership roles within the pharmaceutical contract development and manufacturing (CDMO) industry. This includes various global HR leadership roles at Catalent, where she most recently headed HR for Catalent Biologics and the global Sales & Marketing teams. She previously led Catalent’s Executive and Global Recruiting functions, and her leadership was instrumental in supporting numerous transformations within Catalent’s Global Operations. Prior to joining Catalent, Victoria held various talent acquisition and management roles with GSK Vaccines, Heidrick & Struggles, and Marsh, Inc. Victoria holds a B.A. degree in Psychology/Business from The University of Tulsa.

Jose Ibietatorremendia, SVP, General Counsel and Secretary

Jose Ibietatorremendia

Jose Ibietatorremendia joined Veranova in December 2023 as Senior Vice President, General Counsel and Secretary. Jose has over 20 years of in-house legal leadership experience spanning private equity-backed growth companies through established publicly traded companies. Jose most recently served as VP, Deputy General Counsel and Secretary at Catalent. Prior to that, he served in roles of increasing responsibility at GE Capital, Goldman Sachs, APX, NYSE Blue, and Liquid Holdings Group. Jose began his career at the law firm of Sullivan & Cromwell after clerking for the Hon. Eduardo Robreno in the U.S. District Court for the Eastern District of Pennsylvania. He holds a B.S. in Economics from The Wharton School of the University of Pennsylvania and a J.D. from the University of Pennsylvania Carey Law School.


Advisory Board

Veranova’s advisory board provides expert scientific and strategic guidance.

Dr. Carolyn Bertozzi

Dr. Carolyn Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and a recipient of the 2022 Nobel Prize in Chemistry. She is also the Baker Family Director of Stanford’s Sarafan ChEM-H Institute and an Investigator at the Howard Hughes Medical Institute. Carolyn is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, Accademia Nazionale dei Lincei, the German Academy of Sciences Leopoldina, and a Foreign Fellow of the Royal Society (UK). She is a member of the Board of Directors of Alnylam and of OmniAb, Inc. and a former Director of Eli Lilly.

Carlo de Notaristefani

Carlo de Notaristefani is an accomplished executive with over 30 years of experience building and leading some of the most complex supply chains in the pharmaceutical industry. Carlo led manufacturing operations for Operation Warp Speed, the public/private partnership that delivered billions of vaccine doses during the COVID-19 pandemic. He was previously President & CEO of Global Operations for Teva Pharmaceuticals, President of Technical Operations for Bristol Myers Squibb and held multiple senior leadership positions with Bristol Myers Squibb and Aventis.

John Nason

John Nason has over 30 years of experience in the manufacturing of complex APIs, biologics and finished dose forms. He was previously President of Teva Pharmaceutical Ingredients (TAPI) and Biologics Operations, Senior Vice President of Teva Global Operations, served as Vice President of External Manufacturing and Alliance Management at Bristol Myers Squibb for over ten years, and led bulk API manufacturing for Novartis.

Edward Robinson

Edward Robinson is an accomplished executive with over 30 years of experience building and growing businesses in the CDMO industry. He served as President of Lonza Biologics where he was instrumental in launching Lonza’s US operations. Ed served as Executive Vice President of Cambrex, President of Solutia Pharmaceutical Services, Vice President of Genencor International, and held multiple leadership positions with Snomax Technologies and Eastman Kodak.

Featured insights from our experts

Read more

Antibody-drug conjugate development: challenges and opportunities

By selectively delivering highly potent APIs to cancer cells, they offer a range of improved patient outcomes, including reduced side effects and higher drug tolerability.

Understanding the formation of cocrystals

Cocrystals play an increasingly vital role in drug development, with specialist techniques required to identify and develop them.

Continuous manufacturing (flow chemistry) - the future of pharmaceutical manufacturing

Continuous manufacturing offers several advantages over traditional batch manufacturing, including increased efficiency, reduced waste, and improved product quality.

Veranova is your next great decision

Discover new ways to advance your science with Veranova.

Contact us